164 related articles for article (PubMed ID: 33772035)
1. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
[TBL] [Abstract][Full Text] [Related]
2. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract][Full Text] [Related]
3. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X
Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146
[TBL] [Abstract][Full Text] [Related]
4. Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients.
Kashyap S; Singh MK; Kumar N; Jha J; Lomi N; Meel R; Bakhshi S; Sen S; Singh L
Br J Ophthalmol; 2024 May; 108(6):903-912. PubMed ID: 36918273
[TBL] [Abstract][Full Text] [Related]
5. A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers.
Manoharan M; Mandloi N; Priyadarshini S; Patil A; Gupta R; Iyer L; Gupta R; Chaudhuri A
Front Immunol; 2018; 9():3017. PubMed ID: 30622534
[TBL] [Abstract][Full Text] [Related]
6. Expression of immune checkpoints in T cells of esophageal cancer patients.
Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
[TBL] [Abstract][Full Text] [Related]
7. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
Berezhnoy A; Sumrow BJ; Stahl K; Shah K; Liu D; Li J; Hao SS; De Costa A; Kaul S; Bendell J; Cote GM; Luke JJ; Sanborn RE; Sharma MR; Chen F; Li H; Diedrich G; Bonvini E; Moore PA
Cell Rep Med; 2020 Dec; 1(9):100163. PubMed ID: 33377134
[TBL] [Abstract][Full Text] [Related]
8. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer.
Zhang W; Chen L; Liu J; Chen B; Shi H; Chen H; Qi H; Wu Z; Mao X; Wang X; Huang Y; Li J; Yu Z; Zhong M; Wang T; Li Q
J Exp Clin Cancer Res; 2024 Apr; 43(1):114. PubMed ID: 38627815
[TBL] [Abstract][Full Text] [Related]
10. Expressions of CXCR3 and PD-1 on T cells and their clinical relevance in colorectal cancer.
Wang S; Zhang Y; Chen G; Zhao P; Wang X; Xu B; Yuan L
Int Immunopharmacol; 2024 May; 132():111988. PubMed ID: 38583239
[TBL] [Abstract][Full Text] [Related]
11. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
Li J; Xu J; Yan X; Jin K; Li W; Zhang R
Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.
Llopiz D; Ruiz M; Villanueva L; Iglesias T; Silva L; Egea J; Lasarte JJ; Pivette P; Trochon-Joseph V; Vasseur B; Dixon G; Sangro B; Sarobe P
Cancer Immunol Immunother; 2019 Mar; 68(3):379-393. PubMed ID: 30547218
[TBL] [Abstract][Full Text] [Related]
13. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
[TBL] [Abstract][Full Text] [Related]
14. Enhanced CTLA-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer.
Shin DS; Basak S; Veena MS; Comin-Anduix B; Bhattacharya A; Dong TS; Ko A; Han P; Jacobs J; Moatamed NA; Avila L; Pellegrini M; Wang M; Srivatsan ES
Cancer Med; 2024 May; 13(9):e7212. PubMed ID: 38686626
[TBL] [Abstract][Full Text] [Related]
15. Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models.
Luo J; Ng W; Liu Y; Wang L; Gong C; Zhou Y; Fang C; Zhu S; Yao C
Cancer Immunol Immunother; 2024 Jun; 73(8):137. PubMed ID: 38833034
[TBL] [Abstract][Full Text] [Related]
16. Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy.
Wu S; Jiang H; Fang Z; Wu Y; Jiao J; Fang W; Wu Y; Lang Y; Chen N; Zhong Z; Chen L; Zheng X; Lu B; Jiang J
Cancer Immunol Immunother; 2024 Jun; 73(8):138. PubMed ID: 38833177
[TBL] [Abstract][Full Text] [Related]
17. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.
Shi LZ; Fu T; Guan B; Chen J; Blando JM; Allison JP; Xiong L; Subudhi SK; Gao J; Sharma P
Nat Commun; 2016 Aug; 7():12335. PubMed ID: 27498556
[TBL] [Abstract][Full Text] [Related]
18. Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.
Thibaudin M; Limagne E; Hampe L; Ballot E; Truntzer C; Ghiringhelli F
Cancer Immunol Immunother; 2022 Oct; 71(10):2549-2563. PubMed ID: 35292828
[TBL] [Abstract][Full Text] [Related]
19. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.
Thomas MF; Slowikowski K; Manakongtreecheep K; Sen P; Samanta N; Tantivit J; Nasrallah M; Zubiri L; Smith NP; Tirard A; Ramesh S; Arnold BY; Nieman LT; Chen JH; Eisenhaure T; Pelka K; Song Y; Xu KH; Jorgji V; Pinto CJ; Sharova T; Glasser R; Chan P; Sullivan RJ; Khalili H; Juric D; Boland GM; Dougan M; Hacohen N; Li B; Reynolds KL; Villani AC
Nat Med; 2024 May; 30(5):1349-1362. PubMed ID: 38724705
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
Ho WW; Gomes-Santos IL; Aoki S; Datta M; Kawaguchi K; Talele NP; Roberge S; Ren J; Liu H; Chen IX; Andersson P; Chatterjee S; Kumar AS; Amoozgar Z; Zhang Q; Huang P; Ng MR; Chauhan VP; Xu L; Duda DG; Clark JW; Pittet MJ; Fukumura D; Jain RK
Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]